US Spending on Prescription Drugs Increased Moderately in 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

US Spending on Prescription Drugs Increased Moderately in 2011
Generic-drug incursion and reduced demand contribute to modest gains.

ePT--the Electronic Newsletter of Pharmaceutical Technology

US spending on prescription drugs increased moderately in 2011 reflecting increased generic-drug incursion and lower spending on prescription drugs. Pfizer retained its number one position of the top company of US prescription drug sales, and the generic-drug company Teva Pharmaceutical moved into the top-five companies of US prescription drug sales.

Total healthcare system spending on medicines in the US reached $320 billion in 2011, up 3.7% in nominal terms or 0.5% on a real-per-capita basis, according to a recent report by the IMS Institute for Healthcare Informatics. Branded medicines spending grew 2.2% on a nominal basis and reflected the impact of $14.9 billion lower spending on products that lost their patent exclusivity. In 2011, spending for brands launched within the past two years was $12.2 billion, compared with $8.5 billion in the year-earlier period. Spending on generic drugs, which now account for 80% percent of dispensed prescriptions, increased $5.6 billion in 2011, according to IMS. Overall spending on medicines continued to be concentrated on traditional small-molecule oral pills dispensed through retail pharmacies, even as specialty drugs and biologics experienced higher growth.

Overall per-capita-use of medicines in the US declined slightly in 2011, as physician office visits and nonemergency-room hospital admissions dropped, and older Americans reduced their retail drug use, according to IMS. The number of office visits declined 4.7% while emergency-room admissions, which are relatively small in number, rose 7.4%. Retail prescription usage declined on average 1.1% in 2011 and fell by more than 3% in ten states, reflecting variations in demographics, epidemiology, clinical practice, and payer dynamics. Seniors age 65 and over reduced their use of prescription drugs by 3.1% last year, most notably in the antihypertensive class. Individuals age 19 to 25 increased their use of medicines by 2.0%, notably for attention deficit hyperactivity disorder treatments and antidepressants. This was the only age group that increased drug utilization in 2011.

Nearly one-third of total healthcare spending was concentrated in five therapy areas: oncology, asthma and chronic obstructive pulmonary disease, dyslipidemia, diabetes, and mental health, according to IMS. Each of these therapy areas grew faster than the overall market and exhibited a range of dynamics related to new treatment option usage and growing diagnosis of the related disease.

Product sales and company rankings
On a product basis, Pfizer’s anticholesterol drug Lipitor (atorvastatin) retained its position as the top-selling drug in the United States in 2011 with sales of $7.7 billion, according to data from IMS. Bristol-Myers Squibb’s and Sanofi’s antiplatelet drug Plavix (clopidogrel) was second with US sales of $6.8 billion. AstraZeneca’s Nexium (esomeprazol), a drug to treat gastroesophageal reflux disease, was third with US sales of $6.2 billion. Bristol-Myers Squibb’s Abilify (aripiprazole), an antipsychotic and antidepressant, came in fourth with US sales of $5.2 billion, and GlaxoSmithKine’s Advair Diskus (fluticasone and salmeterol), a drug to treat asthma, was fifth with US sales of $4.6 billion. Rounding out the 10 top-selling prescription drugs in the US were AstraZeneca’s antidepressant Seroquel (quetiapine), Merck & Co’s anti-asthma drug Singulair (montelukast), AstraZenenca’s anticholesterol drug Crestor (rosuvastatin), Eli Lilly’s antidepressant Cymbalta (duloxetine), and Abbott’s Humira (adalimumab), a drug to treat rheumatoid arthritis.

On a company basis, Pfizer retained its top position of US prescription drug sales in 2011, with sales of $25.1 billion followed by AstraZeneca with US sales of $19.9 billion, according to data from IMS. Merck & Co and Novartis closely followed with respective US sales of $19.3 billion and $19.2 billion. Teva Pharmaceutical took the fifth slot with US sales of $15.1 billion. Rounding out the top 10 companies of US prescription sales were Eli Lilly ($14.9 billion), Roche ($14.5 billion), GlaxoSmithKline ($14.2 billion), Amgen ($13.1 billion), and Johnson & Johnson ($12.1 billion). Sanofi, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, and Takeda, respectively, completed the top 15 companies of US prescription drug sales.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here